Vivos Therapeutics annual r&d spending
2021
2022
2023
2024
2025
Vivos Therapeutics R&D Spending Growth & History (VVOS)
Vivos Therapeutics's r&d spending was $100,000 for fiscal 2025.
View full Vivos Therapeutics company overviewVivos Therapeutics annual r&d spending history
| Fiscal year | Period ended | R&D spending | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $100,000 | $0 | 0.00% |
| 2024 | 2024-12-31 | $100,000 | $0 | 0.00% |
| 2023 | 2023-12-31 | $100,000 | −$100,000 | −50.00% |
| 2022 | 2022-12-31 | $200,000 | $0 | 0.00% |
| 2021 | 2021-12-31 | $200,000 | — | — |
Vivos Therapeutics quarterly r&d spending
Q1.21
Q2.21
Q3.21
Q1.22
Q2.22
Q3.22
Q1.23
Q1.23
Q2.23
Q3.23
Q1.24
| Fiscal quarter | Period ended | R&D spending | Change | YoY change |
|---|---|---|---|---|
| Q1 2024 | 2024-03-31 | $100,000 | $0 | 0.00% |
| Q3 2023 | 2023-09-30 | $100,000 | $0 | 0.00% |
| Q2 2023 | 2023-06-30 | $100,000 | $0 | 0.00% |
| Q1 2023 · Mar 31 | 2023-03-31 | $100,000 | $0 | 0.00% |
| Q1 2023 · Feb 28 | 2023-02-28 | $100,000 | — | — |
| Q3 2022 | 2022-09-30 | $100,000 | $0 | 0.00% |
| Q2 2022 | 2022-06-30 | $100,000 | $0 | 0.00% |
| Q1 2022 | 2022-03-31 | $100,000 | $0 | 0.00% |
| Q3 2021 | 2021-09-30 | $100,000 | — | — |
| Q2 2021 | 2021-06-30 | $100,000 | — | — |
| Q1 2021 | 2021-03-31 | $100,000 | — | — |
Vivos Therapeutics r&d spending trends
Between the periods ended 2021-12-31 and 2025-12-31, Vivos Therapeutics's r&d spending decreased from $200,000 to $100,000, a change of −$100,000. The latest reported quarter, Q1 2024, shows $100,000.
About the metric
What research and development spending means
Research and development (R&D) spending covers the costs of creating and improving products, services, software, technologies, and processes. Higher R&D spending may support future innovation, but the amount alone does not show whether those investments will generate returns.
Calculation and source
SEC-reported R&D expense
TickerStat standardizes research and development expense reported in company SEC filings, including the software-specific US-GAAP R&D concept when it is the filer’s primary R&D expense line. It is historical company-reported spending, not an estimate or forecast. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Vivos Therapeutics source filings ↗